Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04292912
Registration number
NCT04292912
Ethics application status
Date submitted
28/02/2020
Date registered
3/03/2020
Date last updated
8/11/2024
Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
Query!
Scientific title
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Query!
Secondary ID [1]
0
0
212669
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Macular Edema
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK2798745
Experimental: GSK2798745 - Eligible participants received single dose of GSK2798745 for 28 days. Participants were instructed to have GSK2798745 about the same time each day.
Treatment: Drugs: GSK2798745
GSK2798745 will be administered.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Abnormal Ophthalmic Examination Findings
Query!
Assessment method [1]
0
0
Ophthalmic examinations for Pupil motility and confrontation visual field examination, slit lamp evaluation of anterior ocular structures, intraocular pressure measurement and optical coherence tomography (OCT) was performed on left and right eye. Participants with data including abnormalities of potential clinical importance is listed here.
Query!
Timepoint [1]
0
0
Up to Day 28
Query!
Primary outcome [2]
0
0
Mean Change From Baseline to Day 28 in Visual Acuity
Query!
Assessment method [2]
0
0
Best-correct visual acuity (BCVA) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The visual function of the study eye was assessed using the ETDRS protocol. ETDRS letters score can be calculated when 20 or more letters are read correctly at 4.0 meters (m); the visual acuity letter score is equal to the total number of letters read correctly at 4.0 m plus 30. If less than 20 letters are read correctly at 4.0 m, the visual acuity letter score is equal to the total number of letters read correctly at 4.0 m (number of letters recorded on line 1.0), plus the total number of letters read correctly at 1.0 m in the first six lines. The score ranges from 0-100 where a higher score represents better visual functioning. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [2]
0
0
Baseline and Day 28
Query!
Primary outcome [3]
0
0
Mean Change From Baseline to Day 28 in Body Weight
Query!
Assessment method [3]
0
0
Physical examination included the measuring of body weight and evaluated at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [3]
0
0
Baseline and Day 28
Query!
Primary outcome [4]
0
0
Mean Change From Baseline to Day 28 in Body Temperature
Query!
Assessment method [4]
0
0
Physical examination included the measuring of body temperature and evaluated at indicated time points. The change from Baseline was calculated by subtracting Baseline value from post-Baseline value.
Query!
Timepoint [4]
0
0
Baseline and Day 28
Query!
Primary outcome [5]
0
0
Mean Change From Baseline to Day 28 in Vital Signs for Systolic Blood Pressure and Diastolic Blood Pressure
Query!
Assessment method [5]
0
0
The change from baseline for Systolic Blood Pressure (SBP) and Diastolic blood Pressure (DBP) was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [5]
0
0
Baseline and Day 28
Query!
Primary outcome [6]
0
0
Mean Change From Baseline to Day 28 in Pulse Rate
Query!
Assessment method [6]
0
0
Pulse rate was measured at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [6]
0
0
Baseline and Day 28
Query!
Primary outcome [7]
0
0
Mean Change From Baseline to Day 28 in 12-lead Electrocardiogram (ECG) Findings
Query!
Assessment method [7]
0
0
The 12-lead ECGs was obtained at indicated timepoints during the study. The standard ECG criteria of potential clinical importance were 1) absolute QTc Interval, \> 450 milliseconds (msec), 2) absolute PR Interval, \<110 msec, 3) absolute QRS Interval, \< 75 msec and 4) increase from baseline in QTc \> 60 msec. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [7]
0
0
Baseline and Day 28
Query!
Primary outcome [8]
0
0
Mean Change From Baseline to Day 28 in Alanine Amino Transferase (ALT), Alkaline Phosphatase (AP), Aspartate Amino Transferase (AST), and Creatine Kinase
Query!
Assessment method [8]
0
0
Summary of changes from baseline in laboratory parameters were assessed. The analysis included liver function tests for ALT, AP, AST, Creatine kinase and evaluated at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [8]
0
0
Baseline and Day 28
Query!
Primary outcome [9]
0
0
Mean Change From Baseline to Day 28 in Calcium, Glucose, Potassium, Sodium, and Urea Nitrogen
Query!
Assessment method [9]
0
0
Summary of changes from baseline in clinical chemistry parameters. The parameters included were calcium, glucose, potassium, sodium and urea nitrogen and evaluated at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [9]
0
0
Baseline and Day 28
Query!
Primary outcome [10]
0
0
Mean Change From Baseline to Day 28 in Creatinine, Total Bilirubin, and Direct Bilirubin
Query!
Assessment method [10]
0
0
Summary of changes from baseline in clinical chemistry parameters. The parameters analyzed were creatinine, total bilirubin and direct bilirubin and evaluated at indicated timepoints. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [10]
0
0
Baseline and Day 28
Query!
Primary outcome [11]
0
0
Mean Change From Baseline to Day 28 in Clinical Chemistry Parameter Values of Protein
Query!
Assessment method [11]
0
0
Summary of changes from baseline in clinical chemistry parameter, Protein. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [11]
0
0
Baseline and Day 28
Query!
Primary outcome [12]
0
0
Mean Change From Baseline to Day 28 in Clinical Chemistry Parameter Values of Cardiac Troponin
Query!
Assessment method [12]
0
0
Summary of changes from baseline in clinical chemistry parameters for Cardiac troponin. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [12]
0
0
Baseline and Day 28
Query!
Primary outcome [13]
0
0
Mean Change From Baseline to Day 28 in Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils, and Platelets
Query!
Assessment method [13]
0
0
Summary of changes from baseline in hematology. The parameters analyzed were Basophils, Eosinophils, Leukocytes, Monocytes, Lymphocytes, Neutrophils and Platelets at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [13]
0
0
Baseline and Day 28
Query!
Primary outcome [14]
0
0
Mean Change From Baseline to Day 28 in Mean Corpuscular Hemoglobin Concentration (MCHC) and Hemoglobin (Hb)
Query!
Assessment method [14]
0
0
Summary of changes from baseline in hematology. The parameters analyzed were MCHC and Hb at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [14]
0
0
Baseline and Day 28
Query!
Primary outcome [15]
0
0
Mean Change From Baseline to Day 28 in Mean Corpuscular Hemoglobin
Query!
Assessment method [15]
0
0
Summary of changes from baseline in mean corpuscular hemoglobin at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [15]
0
0
Baseline and Day 28
Query!
Primary outcome [16]
0
0
Mean Change From Baseline to Day 28 in Mean Corpuscular Volume (MCV)
Query!
Assessment method [16]
0
0
Summary of changes from baseline in hematology MCV assessment. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [16]
0
0
Baseline and Day 28
Query!
Primary outcome [17]
0
0
Mean Change From Baseline to Day 28 in Erythrocytes
Query!
Assessment method [17]
0
0
Summary of changes from baseline in erythrocytes at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [17]
0
0
Baseline and Day 28
Query!
Primary outcome [18]
0
0
Mean Change From Baseline to Day 28 in Hematocrit
Query!
Assessment method [18]
0
0
Summary of changes from baseline in hematocrit parameter at indicated time points. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [18]
0
0
Baseline and Day 28
Query!
Primary outcome [19]
0
0
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Ocular and Non-ocular AEs and SAEs
Query!
Assessment method [19]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. Data has been presented for number of participants with ocular and non-ocular AEs and SAEs.
Query!
Timepoint [19]
0
0
Until follow-up (Up to Day 56)
Query!
Primary outcome [20]
0
0
Mean Change From Baseline to Day 28 in Center Subfield Retinal Thickness as Measured by Spectral-Domain Optical Coherence Tomography (SD-OCT)
Query!
Assessment method [20]
0
0
The SD-OCT effect is a pharmacodynamics (PD) measure of daily repeated dosing of GSK2798745. The mean change from baseline in macular thickness was measured by SD-OCT in the study eye after 28 days of dosing. Measurements was obtained by an appropriately trained photographer/technician using SD-OCT equipment that has been approved by a central reader. The change from baseline was calculated by subtracting baseline value from post-baseline value.
Query!
Timepoint [20]
0
0
Baseline and Day 28
Query!
Secondary outcome [1]
0
0
Plasma Concentrations of GSK2798745
Query!
Assessment method [1]
0
0
Blood samples were collected at indicated time points for plasma concentrations of GSK2798745.
Query!
Timepoint [1]
0
0
Day 7 (Pre-dose, 0.5 hour [h], 1h, 2h, 3h, 4h, 6h, 8h) and Day 28 (Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h)
Query!
Secondary outcome [2]
0
0
Plasma Concentrations of Major Metabolite M1
Query!
Assessment method [2]
0
0
Blood samples were collected at indicated time points for PK analysis of major metabolite of GSK2798745.
Query!
Timepoint [2]
0
0
Day 7 (Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h) and Day 28 (Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h)
Query!
Secondary outcome [3]
0
0
Absorption Rate of GSK2798745
Query!
Assessment method [3]
0
0
Blood samples were collected at indicated time points for PK analysis of GSK2798745 absorption rate.
Query!
Timepoint [3]
0
0
Day 28
Query!
Secondary outcome [4]
0
0
Clearance of GSK2798745
Query!
Assessment method [4]
0
0
Blood samples were collected at indicated time points for PK parameters including clearance of GSK2798745.
Query!
Timepoint [4]
0
0
At Day 28
Query!
Secondary outcome [5]
0
0
Volume of Distribution of GSK2798745
Query!
Assessment method [5]
0
0
Blood samples were collected at indicated time points for PK parameters including volume of distribution of GSK2798745.
Query!
Timepoint [5]
0
0
At Day 28
Query!
Secondary outcome [6]
0
0
Maximum Observed Plasma Concentration (Cmax) of GSK2798745
Query!
Assessment method [6]
0
0
Blood samples were collected at indicated time points for PK parameters including Cmax of GSK2798745.
Query!
Timepoint [6]
0
0
At Day 28
Query!
Secondary outcome [7]
0
0
Area Under Concentration-Time Curve (AUC) Over Dosing Interval of GSK2798745
Query!
Assessment method [7]
0
0
Blood samples were collected at indicated time points for PK parameters including AUC of GSK2798745.
Query!
Timepoint [7]
0
0
At Day 28
Query!
Eligibility
Key inclusion criteria
* At least 18 to 75 years of age inclusive, at the time of signing the informed consent.
* Diagnosis of diabetes mellitus (type 1 or type 2).
* Confirmation of DME with center involvement in at least one eye by fluorescein angiography.
* Confirmation of retinal thickening (diabetic macular edema) involving the center of the fovea in the study by Investigator.
* Best Corrected Visual Acuity (BCVA) letter score of 80 letter or worse (Snellen equivalent: equivalent to 20/25) or worse in the study eye.
* Safe to withhold treatment of the study eye with laser photocoagulation, intravitreal steroid injection, or intravitreal vascular endothelial growth factor (VEGF) inhibitor for the duration of the study.
* Body weight greater than equal to (>=) 50 kilograms (kg) and Body mass index (BMI) within the range 18 to 43 kg per square meter (inclusive) at screening.
* Male participants must agree to refrain from donating sperm, plus either be abstinent from heterosexual or homosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use acceptable contraception/barrier to use acceptable contraceptive methods if their partner is of childbearing potential. This criterion must be followed from the first dose of study treatment until the follow-up visit.
* A female participant is eligible to participate if she is not of childbearing potential.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Additional eye disease in the study eye that in the opinion of the Investigator could compromise assessment.
* History of choroidal neovascularization in the study eye, or current choroidal neovascularization in the fellow eye requiring treatment.
* Active Proliferative diabetic retinopathy (PDR) in the study eye or untreated active PDR in the fellow eye.
* Ischemic maculopathy on fluorescein angiography.
* Intraocular surgery or laser photocoagulation in the study eye within 90 day.
* Use of intravitreal ranibizumab,or bevacizumab within 42 days (6 weeks), or aflibercept within 56 days (8 weeks) of dosing in the study eye.
* Use of intraocular steroids in the study eye within 180 days of dosing.
* Use of or expected need for intravitreal or intraocular treatment in the study eye during course of the study.
* Use of any systemically administered anti-angiogenic agent within 6 months of dosing.
* Evidence of vitreomacular traction as determined by the Investigator.
* Uncontrolled intraocular pressure in the study eye despite treatment with glaucoma medication.
* Within 6 months prior to the Screening Visit, use of medications known to be toxic to the retina, lens or optic nerve
* Uncontrolled diabetes as indicated by glycated hemoglobin (HbA1c) >12% at Screening.
* Active ulcer disease or gastrointestinal bleeding by history within 6 months of screening or by exam at the time of screening.
* Certain type of liver disease.
* Participant who, in the Investigator's opinion, poses a significant suicide risk.
* History or current evidence of any serious or clinically significant cardiac, gastrointestinal, renal, endocrine, neurologic, hematologic, infectious or other condition that is uncontrolled.
* Corrected (QTc) interval >450 milliseconds (msec) or QTc >480 msec in participants with bundle branch block.
* Use of certain medications that may interfere with the study medication or eye assessments (these will be identified by the study doctor).
* Current enrollment, or recent participation in a study of investigational intervention or medical research.
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study.
* Any other reason the investigator deems the participant should not participate in the study.
* Other protocol-defined inclusion/exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/09/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/04/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
16
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Castle Hill
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Westmead
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2154 - Castle Hill
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Ohio
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
New Zealand
Query!
State/province [6]
0
0
Christchurch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
Query!
Trial website
https://clinicaltrials.gov/study/NCT04292912
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
IPD for this study will be made available via the Clinical Study Data Request site.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Query!
Available to whom?
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://clinicalstudydatarequest.com
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/12/NCT04292912/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/12/NCT04292912/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04292912
Download to PDF